T-Cell Engagers

T-cell engagers are a unique type of fusion protein that is designed to harness the power of the patient’s own immune system to identify and eliminate cancer. Bispecific T-cell Engager (BiTE®) technology is designed to overcome cancer cells’ evasion of the immune system by engaging patients’ own T cells to directly target cancer cells. As the innovator behind the first globally approved BiTE molecule in hematology and the first FDA approved BiTE molecule for the treatment of a solid tumor, Amgen remains committed to bringing this innovative modality to more patients.

$name
$name

Oncology

The Mechanism of Action of BiTE® Technology

VIEW VIDEO
Arrow
❮1 / 3❯
$name
$name

Oncology

How BiTE® Technology Targets Cancer

Open PDF
❮2 / 3❯
$name
$name

Oncology

AACR 2022: Science in Focus Twitter Spaces

Read MoreArrow
❮3 / 3❯

Hematological Malignancies

Amgen was the first to develop a globally approved BiTE molecule in hematology and has delivered a series of “firsts” that have propelled the science of T-cell engagers forward.

Solid Tumors

Amgen was the first to develop an FDA approved BiTE molecule in a solid tumor, and continues to accelerate high-impact medicines for the toughest cancers with investigational T-cell engagers in solid tumors, including prostate cancer.